A Phase I/II Study of INCMGA00012 Immunotherapy with Gemcitabine and Docetaxel in People with Advanced Soft Tissue Sarcoma

Full Title

A Multi-cohort Study of Retifanlimab with or without Gemcitabine and Docetaxel in Patients with Advanced Sarcoma

Purpose

The purpose of this study is to assess the safety and effectiveness of giving the investigational immunotherapy drug INCMGA00012 in combination with gemcitabine and docetaxel in patients with inoperable or metastatic soft tissue sarcoma. Gemcitabine and docetaxel are standard treatments for this disease; researchers believe that adding INCMGA00012 may make treatment more effective.

INCMGA00012 works by boosting the power of the immune system to recognize and fight cancer. All of the medications in this study are given intravenously (by vein).

Protocol
20-316
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Newly Diagnosed
Investigator
Sandra P. D'Angelo
Co-Investigators
William D. Tap
Diseases
Sarcomas › Leiomyosarcoma
Sarcomas › Soft Tissue Sarcoma
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT04577014
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description